Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;62(6):69.
doi: 10.3892/ijo.2023.5517. Epub 2023 May 5.

Long non‑coding RNAs in multiple myeloma (Review)

Chenbo Yang  1 , Yinghao Liang  2 , Jiao Shu  1 , Shuaiyuan Wang  1 , Yichen Hong  2 , Kuisheng Chen  1 , Miaomiao Sun  1
Affiliations
Review

Long non‑coding RNAs in multiple myeloma (Review)

Chenbo Yang et al. Int J Oncol. 2023 Jun.

Abstract

Multiple myeloma (MM) is one of the three major malignancies of the hematological system in middle‑aged and older individuals. The incidence of MM increases with age and due to its drug resistance and high recurrence, MM seriously harms human health. Long non‑coding RNAs (lncRNAs) are RNA molecules with a length of >200 nt and rarely encode proteins. Numerous studies reported that lncRNAs regulate carcinogenesis and cancer progression. MM‑associated lncRNAs affect features of tumor cells, including proliferation, apoptosis, adhesion and treatment resistance. The present review aims to summarize the latest findings on the roles of lncRNAs in MM to deepen the understanding of this field and provide insight for developing specific diagnostic tools and effective treatment strategies for MM, including novel biomarkers and targeted lncRNA therapeutics.

Keywords: drug resistance; long non‑coding RNA; molecular mechanism; multiple myeloma; prognosis; tumor progression.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Molecular regulatory networks of multiple myeloma-associated lncRNAs. LncRNA, long non-coding RNA; miRNA, microRNA.
Fige 2
Fige 2
Roles of MM-associated lncRNAs in tumors. LncRNA, long non-coding RNA; TME, tumor microenvironment; MM, multiple myeloma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, et al. Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221–1227. - PMC - PubMed
    1. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study. Leukemia. 2017;31:2443–2448. - PubMed
    1. van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–427. - PubMed
    1. Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816. - PMC - PubMed
    1. Yan H, Bu P. Non-coding RNA in cancer. Essays. Biochem. 2021;65:625–639. - PMC - PubMed